Natixis Avidity Biosciences, Inc. Call Options Transaction History
Natixis
- $17.6 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RNA
# of Institutions
255Shares Held
107MCall Options Held
224KPut Options Held
161K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$333 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.23MShares$289 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$270 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$255 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$220 Million0.06% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.63B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...